Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cedicatedilimab + bevacizumab as adjuvant therapy after radical resection of biliary tract cancer
ChiCTR2600131567Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cedicatedilimab and bevacizumab in biliary cancer, intrahepatic cholangiocarcinoma (ICC), hilar cholangiocarcinoma (HC) and 2 more, sponsored by Ruijin Hospital. Primary endpoint: 1-year disease-free survival rate. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
cedicatedilimabbevacizumab
03
Conditions
biliary cancerintrahepatic cholangiocarcinoma (ICC)hilar cholangiocarcinoma (HC)distal cholangiocarcinoma (dCCA)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2600131567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131567.